Results 221 to 230 of about 160,542 (279)

Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma. [PDF]

J Immunother Cancer
Lee JB, Baek S, Kim DK, Kwon BE, Ahn JS, Nagasaka M, Davar D, Park H, Kim H, Im J, Yang J, Yang E, Shin GH, Choi S, Kwon JE, Kim JM, Kang SY, Kim Y, Park SY, Kim JH, Oh HS, Chalita M, Min A, Cho BC.   +23 more
europepmc   +1 more source

Microbiome–Driven Carcinogenesis and Circulating Microbial Signals in Genitourinary Cancers

Cancer Science, EarlyView.
Experimental BBN models link gut microbial metabolism and diet‐microbiome interactions to urothelial carcinogenesis, while circulating extracellular vesicle‐associated bacterial DNA signals may reflect tumor immune contexture and immune checkpoint inhibitor outcomes in urothelial and renal cell carcinoma.
Atsunari Kawashima, Kentaro Jingushi, Takuro Saito, Toshihiro Uemura, Akinaru Yamamoto, Nesrine Sassi, Hiromu Horitani, Shunsuke Inoguchi, Yuki Horibe, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Norio Nonomura   +12 more
wiley   +1 more source

Pneumonitis During Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer: A Case Report. [PDF]

Cureus
Bakalis A, Bouliaris K, Psoma F, Sgantzou IK, Lambrodimou G.   +4 more
europepmc   +1 more source

From Tumour to Bloodstream: Advancing PD‐L1 Testing With Liquid Biopsies in Non‐Small Cell Lung Cancer

Cytopathology, EarlyView.
This review explores liquid biopsy as a complementary approach to tissue‐based PD‐L1 assessment in advanced NSCLC treated with immune checkpoint inhibitors. Focusing on circulating tumour cells, extracellular vesicles, and circulating tumour DNA, it summarises current evidence, technical challenges, and future perspectives for personalised ...
R. Leporati, V. Callegari, A. Ancora, M. Palmieri, B. Riccò, E. Cabitza, L. Trudu, K. Di Emidio, C. Chiavelli, A. Eccher, I. Mastrolia, V. Catani, S. Bettelli, G. Guaitoli, M. Dominici, F. Bertolini   +15 more
wiley   +1 more source

Pembrolizumab and Enfortumab-Induced Immunotherapy Myocarditis. [PDF]

Cureus
Lodha C, Basile EJ, Wright CC.
europepmc   +1 more source

Real‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Adjuvant immune checkpoint inhibitors (ICI) and targeted therapy (TT) have revolutionized treatment management for patients with melanoma. However, the current German S3 guideline does not differentiate between patients with and without adjuvant therapy in its recommendations for imaging intervals and follow‐up monitoring, leading to
Markus Reitmajer, Elisabeth Livingstone, Lucie Heinzerling, Kai‐Martin Thoms, Frank Meiss, Markus V. Heppt, Anja Gesierich, Konstantin Drexler, Friedegund Meier, Max Schlaak, Andrea Forschner, Lisa Zimmer   +11 more
wiley   +1 more source

The efficacy and safety of four different PD-1 checkpoint inhibitors in advanced non-small cell lung cancer: a real-world retrospective study. [PDF]

Front Oncol
Wang H, Xing Z, Ren X, Bai R, Zou Y, Wang Y, Zhang H, Zhang Z.   +7 more
europepmc   +1 more source

Complete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Complete lymph node dissection (CLND) is the standard of care in patients with regional nodal melanoma macrometastasis. However, evidence on surgical procedures in the era of adjuvant systemic therapies is lacking. Patients and Methods This retrospective multi‐center study included stage IIIB–D melanoma patients with ...
Kristine E. Mayer, Jessica C. Hassel, Jannik Sambale, Michael Erdmann, Mihaela‐Anca Sindrilaru, Julia Oberschmied, Alexander Thiem, Dirk Tomsitz, Jana Knuever, Max Schlaak, Carola Berking, Christian Posch, Tilo Biedermann, Oana‐Diana Persa   +13 more
wiley   +1 more source

Effect of histology on the efficacy of first-line immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and network meta-analysis. [PDF]

Front Immunol
Li S, He T, Chen J, Liu T, Zhao X, Dang J.   +5 more
europepmc   +1 more source

Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo, Nikolina Ivanovic, Patrick Turko, Lukas Kraehenbuehl, Mitchell Levesque, Reinhard Dummer, Barbara Meier‐Schiesser   +6 more
wiley   +1 more source